''One size fits all'' unique drug to eradicate multiple viral species simultaneously from the central nervous system of co-infected individuals

Informazioni relative al progetto

NOVIRUSES2BRAIN

ID dell’accordo di sovvenzione: 828774

DOI 10.3030/828774

Data della firma CE 17 Dicembre 2018

Data di avvio 1 Settembre 2019

Data di completamento 31 Agosto 2025

Finanziato da

• EXCELLENT SCIENCE - Future and Emerging Technologies (FET)

Costo totale € 3 933 965,63

Contributo UE € 3 933 965,63

Coordinato da

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES
Portugal

Risultati finali

Open Research Data Pilot (1)

Data Management Plan

"A Data Management Plan (DMP) will be elaborated including what data the project will generate, whether and how it will be made accessible for verification and re-use, and how it will be curated and preserved. Through this DMP the Consortium can define certain datasets to remain closed according to the principle ""as open as possible, as closed as necessary""."

Websites, patent fillings, videos etc. (1)

Website and project logo

Dedicated website will be launched and a project logo, as the first communication package of the project.

Documents, reports (2)

First technical/scientific review meeting report

The Report will include the draft agenda and the presentations to be delivered during the review meeting with the REAEC

Second technical/scientific review meeting report

The Report will include the draft agenda and the presentations to be delivered during the review meeting with the REAEC

Pubblicazioni

Peer reviewed articles (4)

A designed cyclic analogue of gomesin has potent activity against Staphylococcus aureus biofilms

Autori: Dias, Susana Pinto, Sandra Silva-Herdade, Ana S. Cheneval, Olivier Craik, David J Coutinho, Ana Castanho, Miguel A. R. B. Henriques, Sónia T. Veiga, Ana Salomé
Pubblicato in: J Antimicrob Chemother., 2022, ISSN 0305-7453
Editore: Oxford University Press
DOI: 10.1093/jac/dkac309

Penetrating the Blood-Brain Barrier with New Peptide-Porphyrin Conjugates Having anti-HIV Activity.

Autori: Mendonça, Diogo A. Bakker, Mariët Cruz-Oliveira, Christine Neves, Vera Angeles Jiménez, Maria Defaus, Sira Cavaco, Marco Veiga, Ana Salomé Cadima Couto, Carla Iris Castanho, Miguel A. R. B. Andreu, David Todorovski, Toni
Pubblicato in: Bioconjugate Chem., 2021, ISSN 1043-1802
Editore: American Chemical Society
DOI: 10.1021/acs.bioconjchem.1c00123

Targeting Zika Virus with New Brain- and Placenta-Crossing Peptide–Porphyrin Conjugates

Autori: Toni Todorovski ,Diogo A. Mendonça ,Lorena O. Fernandes-Siqueira, Christine Cruz-Oliveira ,Giuseppina Guida 1,Javier Valle 1,Marco Cavaco 2ORCID,Fernanda I. V. Limas 3,Vera Neves 2ORCID,Íris Cadima-Couto 2,Sira Defaus 1,Ana Salomé Veiga 2,Andrea T. Da Poian 3,Miguel A. R. B. Castanho 2 and David Andreu
Pubblicato in: Pharmaceutics, 2022, ISSN 1999-4923
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics14040738

Antiviral Peptide-Based Conjugates: State of the Art and Future Perspectives

Autori: David Andreu; Daniela Kalafatovic; Toni Todorovski
Pubblicato in: Pharmaceutics, 2023, ISSN 1999-4923
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics15020357